Third-party tested · 1–3 day shippingShop the catalog
Back to catalog
CJC-1295 no DAC - Emetrix Research Labs branded vial

Growth Hormone Studies

CJC-1295 no DAC

MOD GRF 1-29 — growth hormone secretagogue research.

In Stock
Lyophilized Powder
$58.00
Research-use disclaimer: For research use only. Not for human or veterinary use.

Specifications

Formula
C152H252N44O42
Molecular Weight
3367.94 g/mol
Storage
Store at 2-8°C / 36-46°F
Form
Lyophilized Powder

Description

A modified growth hormone-releasing hormone analog used in research on endocrine signaling and body composition.

Certificates of Analysis

Batch EMT-1295-2407-B

Tested: 2024-07-12

Purity: 98.85%

View COA

Compound Guide

What is CJC-1295 (No DAC)?

Amplified Natural GH Pulse

Growth HormoneRecoveryBody Composition

CJC-1295 without DAC — also called Mod GRF (1-29) — is a modified growth-hormone-releasing hormone fragment. Four amino-acid substitutions extend its half-life past native GHRH while keeping the release pattern pulsatile rather than continuous, which is why it is studied as a pairing partner for ghrelin agonists.

Areas of Research Interest

Summarized from published research findings. Not medical guidance or prescribing information.

Pulsatile Release

Preserves the natural episodic GH rhythm rather than producing a flat serum elevation.

Recovery Endpoints

Studied for post-exertion recovery and lean-tissue maintenance in combination protocols.

Sleep Architecture

Evening administration is examined against slow-wave sleep measures.

Lipolysis Models

GH-axis elevation is associated with increased fat-substrate utilization.

Synergy

Most published designs pair it with Ipamorelin for an amplified combined pulse.

Short Half-Life

No-DAC form clears quickly, avoiding the sustained saturation seen with DAC variants.

Reconstitution

  • 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL
  • 2 mg vial + 2 mL bacteriostatic water = 1.0 mg/mL
  • At 2.5 mg/mL, 1 unit on a U-100 syringe = 25 mcg
Open the peptide calculator

Suggested research protocol

  • Route studied: subcutaneous, typically administered together with Ipamorelin in the same syringe.
  • Timing: before sleep and/or post-exertion, away from food.
  • Cycle: 5 days on / 2 days off, in 8–12 week research blocks.
  • Refrigerate after reconstitution; use within 30 days.

Dosing Reference

PhasePer administrationU-100 units @ 2.5 mg/mL
Introductory100 mcg4 units
Standard100–200 mcg4–8 units
Paired with Ipamorelin100 mcg each4 units each

Handling & Notes

  • Food — particularly fats and carbohydrates — blunts the GH response; a fasted window is standard in study design.
  • Transient flushing or head-rush sensations are logged and short-lived.
  • Store lyophilized vials away from light.

This guide is provided for informational and research reference only. CJC-1295 (No DAC) is intended for laboratory research use exclusively and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary consumption.